First Targeted Therapy for Patients With the KRAS G12C Mutation Approved in the European Union
Approval Based on Pivotal CodeBreaK 100 Data Demonstrating Durable Responses and a Favorable Benefit-Risk Profile With LUMYKRAS
LUMYKRAS Now Approved in 35 Countries Around the World Through Most Advanced KRAS G12C Clinical Development Program
https://finance.yahoo.com/news/european-commission-approves-lumykras-sotorasib-050000155.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.